7.32
                                            Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Gewinn- und Verlustrechnung
                
            Vierteljährlich
                
            
        *Alle Zahlen in Millionen
    
| Enddatum des Zeitraums | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 
| Revenues | 
                                            
                                        12.24%
                                     163.35 | 145.53 | 131.53 | 117.08 | 109.33 | 
| Cost Of Revenue | 
                                            
                                        38.75%
                                     2.798 | 4.568 | 6.094 | 3.211 | 1.699 | 
| Gross Profit | 
                                            
                                        13.90%
                                     160.56 | 140.97 | 125.44 | 113.87 | 107.63 | 
|  | 
                                            
                                        9.21%
                                     130.77 | 119.74 | 129.95 | 106.18 | 98.87 | 
| Benefits Costs and Expenses | 
                                            
                                        8.35%
                                     156.87 | 144.78 | 157.53 | 130.53 | 121.83 | 
| Costs And Expenses | 
                                            
                                        7.45%
                                     133.57 | 124.31 | 136.04 | 109.39 | 100.57 | 
| Operating Income/Loss | 
                                            
                                        40.32%
                                     29.79 | 21.23 | -4.508 | 7.692 | 8.761 | 
| Nonoperating Income/Loss | 
                                            
                                        13.83%
                                     -23.30 | -20.47 | - | - | - | 
| Income/Loss From Continuing Operations Before Tax | 
                                            
                                        755.67%
                                     6.486 | 0.758 | -25.99 | -13.45 | -12.50 | 
| Income Tax Expense/Benefit | 
                                            
                                        92.98%
                                     1.401 | 0.726 | 0.804 | 0.586 | 0.172 | 
| Income/Loss From Continuing Operations After Tax | 
                                            
                                        15,791%
                                     5.085 | 0.032 | -26.80 | -14.03 | -12.67 | 
|  | 
                                            
                                        15,791%
                                     5.085 | 0.032 | -26.80 | -14.03 | -12.67 | 
| Preferred Stock Dividends And Other Adjustments | - | - | - | - | - | 
| Attributable To Noncontrolling Interest | - | - | - | - | - | 
| Basic Average Shares | 
                                            
                                        0.30%
                                     209.52 | 208.88 | 0.23 | 206.91 | 206.43 | 
| Diluted Average Shares | 
                                            
                                        2.15%
                                     219.89 | 215.26 | 0.23 | 206.91 | 206.43 | 
| Basic Earnings Per Share | 0.02 | - | -0.13 | -0.07 | -0.06 | 
| Diluted Earnings Per Share | 0.02 | - | -0.13 | -0.07 | -0.06 | 
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | - | - | - | - | - | 
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):
                 
            
         
                     
                             Holen Sie sich die Stockscreener-App
                    Holen Sie sich die Stockscreener-App
                